
Merit Medical Ribbon Cutting & Facility Tour
July 16, 2026

Merit Medical Systems on Wednesday marked an important milestone with a ribbon-cutting ceremony celebrating the completion of an expansive new distribution center in South Jordan. The center, across the street from the Merit campus, adds more than 210,000 square feet of new construction and state-of-the-art technology to move product efficiently to customers in Utah and around the world. Speakers included Merit President and CEO, Martha Aronson, Merit Board Chair, Sen. Ann Millner, and South Jordan Mayor Dawn Ramsey.
Merit President and CEO, Martha Aronson, addressed the gathering of government officials, business leaders, and other distinguished guests who gathered to mark the occasion.
Staff from the offices of Sens. Mike Lee and John Curtis, and Reps. Blake Moore, Burgess Owens, and Mike Kennedy were also on hand to support this significant investment in Utah.
“Today’s opening of Merit’s new distribution center reflects the company’s longstanding commitment to Utah, the City of South Jordan, its employees, and most importantly the life-enhancing innovations they bring to patients every day, said Kelvyn Cullimore of BioUtah. Merit, a true Utah success story, is well positioned to continue to grow and advance health.”
Other dignitaries taking the stage to recognize Merit’s achievement included state Sen. Ann Milner, Merit Board Chair; City of South Jordan Mayor Dawn Ramsey; and Salt Lake County Mayor Jenny Wilson.
Attendees were treated to a tour of the facility following the program.


Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome













